65,437 trials
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Safety of Treatment With NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) — 26; 26; 24; 3 Participants
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -33.1; -27.8 mm Hg
Type 2 Diabetes Mellitus
Primary: Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) — 47.25; 48.91; 52.89…
Type 2 Diabetes Mellitus
Primary: Change in Time-averaged Glucose During a 24 Hour Period — -41.65; -29.56 mg/dL — p=<.001
Chronic Hepatitis C · Liver Fibrosis
Primary: Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3). — 44; 29…
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib — 6.7; 7.0 Months Survival
Diabetic Macular Edema
Primary: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From…
Sickle Cell Disease
Primary: Number of Participants With Adverse Events After Start of ICL670 — 131; 49; 1; 2 participants
Acute Migraine
Primary: Pain Relief (PR) — 102; 21; 100; 78 attacks — p=<0.001
Attention Deficit Hyperactivity Disorder
Primary: Hour 4 Permanent Product Math Test Attempted Score (PERMP-Attempted) — 74.8; 103.5 Problems attempted — p=<0.0001
Type 2 Diabetes
Primary: Number of Participants Experiencing Clinical and Laboratory Adverse Events (CAEs and LAEs) — 4; 5; 0; 0 participants
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
Alkaptonuria
Primary: Change in Total ROM Worse Hip — -9.1; 1.6 degrees
Osteoporosis
Primary: Number of Participants With Improvement in Bone Mineral Density (BMD) of Spine After Therapy — 10; 9 participants
Cold Sore
Primary: Clinical Assessment Performed by the Investigator and Skin Temperature at the Cold Sore. — 39; 32 participants